



August 15, 2024

COR/2024/08-01

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Director Enforcement Securities & Exchange Commission of Pakistan NIC Building Jinnah Avenue, Blue Area Islamabad.

Dear Sir,

## **DISCLOSURE OF MATERIAL INFORMATION**

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

We are pleased to inform you that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has successfully launched human insulin under the brand name "Ferulin". This launch marks a significant milestone in our commitment to STOP DIABETES, expand our product portfolio and enhance the availability of life-saving medicines in the market. Ferulin has been developed with the highest quality standards and is intended to provide effective and affordable diabetes treatment to patients across Pakistan.

Being the 1st Biotech Plant in Pakistan, BF Biosciences Limited has been committed to the production of essential medicines for the treatment of HCV, Cancer, Cardiology and other therapeutic areas for over a decade. We are confident that Ferulin will positively impact our subsidiary's growth and will further strengthen our mission to address unmet patient needs.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yours truly,

Syed Ghausuddin Saif Company Secretary

